John Fox, MD, MHA: An important element to the pathways program is to assess what the patient’s preferences and goals of care are. Almost all patients will want an initial round of some kind of treatment, whether it be chemotherapy or targeted therapy or immunotherapy. But after they fail or become resistant to initial therapy, the patient and physician have a decision to make about what the next round of therapy is or even if, in fact, the patient wants additional treatment.
For patients who choose to have additional treatment, there are multiple second-line options in non—small cell lung cancer: chemotherapy, chemotherapy plus an anti-VEGF (anti-vascular endothelial growth factor), or an anti-VEGF or immunotherapy. I think that the emerging data, especially around immunotherapy, when compared to chemotherapy with docetaxel, is that outcomes are better with immunotherapy compared to chemotherapy alone.
In fact, patients who are PD-L1 (programmed death-ligand 1) positive, at a threshold of 50% or more, have even better outcomes than those who don’t. So, I think the choice for physicians is, what information do they have to share with patients about what the likely outcomes are, given those multiple different choices? And again, as a health plan, as long as you’re consistent with the evidence, as long as the options are in the NCCN Guidelines, we’ll allow them to make that choice.
I think the interesting emerging concept, now with physicians at risk for the total cost of care, is, what choices are they going to make? And what minor improvements in health outcomes or overall survival are going to be important to them? If you look, for example, at Keytruda in second-line non—small cell lung cancer, you get a 17-month overall survival benefit compared to docetaxel, which is around 8 or 9 months—a significant benefit.
For patients who have a negative PD-L1 titer or have a lower PD-L1 titer, there are still multiple options available (although the differences between the outcomes in those different regimens are much narrower). For example, in patients who get PD-L1 or immunotherapy versus chemotherapy plus anti-VEGF therapy, the differences aren’t significant. Certainly, they are better than chemotherapy alone, but those options and the side effects have to be considered in choosing which therapy a patient wants to receive.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Review: One-Shot Etranacogene Dezaparvovec Represents Game-Changing Gene Therapy for Hemophilia B
May 3rd 2024More than 20 years of gene therapy clinical research have led to etranacogene dezaparvovec’s use in hemophilia B, according to authors of a recent review—and it takes its place in a line of current and potentially many future genomic medicines for a range of diseases.
Read More